Compare AbCellera Biologics Inc (ABCL) vs Alcon AG (ALC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Alcon AG — how do they compare? AbCellera Biologics Inc trades at $9.07 (market cap $2.99B), while Alcon AG trades at $72.42 (market cap $36.44B). The key difference: Alcon AG is far larger — about 12.2× AbCellera Biologics Inc's market cap, and Alcon AG pays a 0.48% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ALC | |
|---|---|---|
Market Cap | $2.99B | $36.44B |
Sector | Health | Health |
52-Week High | $9.76 | $90.12 |
52-Week Low | $2.78 | $62.02 |
Enterprise Value | $2.58B | $40.28B |
Dividend Yield | — | 0.48% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →
